In the post-hoc subanalysis of the rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF) AF trial, the rate of major bleeding was higher among patients with anticoagulated AF with aortic or MR compared to those without VHD (30). The gene discussed is F10; the disease is atrial fibrillation.